NewAmsterdam Pharma Company N.V. (NAMS)
(Delayed Data from NSDQ)
$18.82 USD
-0.28 (-1.47%)
Updated May 24, 2024 03:59 PM ET
After-Market: $18.79 -0.03 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for NewAmsterdam Pharma Company NV falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 14 | 103 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 14 | 103 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 197 | 174 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -183 | -71 | -1 | 0 | 0 |
Non-Operating Income | 6 | -11 | 6 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -177 | -82 | 4 | 0 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -177 | -82 | 4 | 0 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -177 | -82 | 4 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -183 | -71 | -1 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -183 | -71 | -1 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 82.30 | 81.30 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.15 | -1.01 | NA | NA | NA |
Diluted Net EPS (GAAP) | -2.15 | -1.01 | 0.24 | -0.04 | NA |
Fiscal Year end for NewAmsterdam Pharma Company NV falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 1.40 | NA | NA | NA | 8.63 |
Cost Of Goods | 0.00 | NA | NA | NA | 0.00 |
Gross Profit | 1.40 | NA | NA | NA | 8.63 |
SG&A, R&D, and Dept/Amort Expenses | 56.88 | 0.00 | 0.00 | 0.00 | 48.48 |
Income After SG&A, R&D, and Dept/Amort Expenses | -55.48 | 0.00 | 0.00 | 0.00 | -39.85 |
Non-Operating Income | -38.29 | NA | NA | NA | -2.17 |
Interest Expense | 0.00 | NA | NA | NA | 0.00 |
Pretax Income | -93.77 | NA | NA | NA | -42.02 |
Income Taxes | 0.00 | NA | NA | NA | 0.00 |
Minority Interest | 0.00 | NA | NA | NA | 0.00 |
Investment Gains/Losses | 0.00 | NA | NA | NA | 0.00 |
Other Income/Charges | 0.00 | NA | NA | NA | 0.00 |
Income From Cont. Operations | -93.77 | NA | NA | NA | -42.02 |
Extras & Discontinued Operations | 0.00 | NA | NA | NA | 0.00 |
Net Income (GAAP) | -93.77 | NA | NA | NA | -42.02 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 88.38 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.62 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -1.06 | NA | NA | NA | NA |